Fitxa

oai_dc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

   1. <dc:title>3D hepg2 cell-based cell transformation assay.</dc:title>

   2. <dc:creator>Martín Levy, Raquel</dc:creator>

   3. <dc:contributor>Sovadinová, Iva</dc:contributor>

   4. <dc:description>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</dc:description>

   5. <dc:description>pre-print</dc:description>

   6. <dc:description>1016 KB</dc:description>

   7. <dc:date>2021-08-30T12:03:46Z</dc:date>

   8. <dc:date>2021-08-30T12:03:46Z</dc:date>

   9. <dc:date>2021</dc:date>

   10. <dc:type>bachelorThesis</dc:type>

   11. <dc:identifier>http://hdl.handle.net/10641/2409</dc:identifier>

   12. <dc:language>eng</dc:language>

   13. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>

   14. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>

   15. <dc:rights>openAccess</dc:rights>

   </oai_dc:dc>

didl

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <d:DIDL schemaLocation="urn:mpeg:mpeg21:2002:02-DIDL-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/did/didl.xsd">

   1. <d:DIDLInfo>

      1. <dcterms:created schemaLocation="http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/dcterms.xsd">2021-08-30T12:03:46Z</dcterms:created>

      </d:DIDLInfo>

   2. <d:Item id="hdl_10641_2409">

      1. <d:Descriptor>

         1. <d:Statement mimeType="application/xml; charset=utf-8">

            1. <dii:Identifier schemaLocation="urn:mpeg:mpeg21:2002:01-DII-NS http://standards.iso.org/ittf/PubliclyAvailableStandards/MPEG-21_schema_files/dii/dii.xsd">urn:hdl:10641/2409</dii:Identifier>

            </d:Statement>

         </d:Descriptor>

      2. <d:Descriptor>

         1. <d:Statement mimeType="application/xml; charset=utf-8">

            1. <oai_dc:dc schemaLocation="http://www.openarchives.org/OAI/2.0/oai_dc/ http://www.openarchives.org/OAI/2.0/oai_dc.xsd">

               1. <dc:title>3D hepg2 cell-based cell transformation assay.</dc:title>

               2. <dc:creator>Martín Levy, Raquel</dc:creator>

               3. <dc:contributor>Sovadinová, Iva</dc:contributor>

               4. <dc:description>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</dc:description>

               5. <dc:date>2021-08-30T12:03:46Z</dc:date>

               6. <dc:date>2021-08-30T12:03:46Z</dc:date>

               7. <dc:date>2021</dc:date>

               8. <dc:type>bachelorThesis</dc:type>

               9. <dc:identifier>http://hdl.handle.net/10641/2409</dc:identifier>

               10. <dc:language>eng</dc:language>

               11. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>

               12. <dc:rights>openAccess</dc:rights>

               13. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>

               </oai_dc:dc>

            </d:Statement>

         </d:Descriptor>

      3. <d:Component id="10641_2409_1">

         1. <d:Resource mimeType="application/pdf" ref="http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf" />

         </d:Component>

      </d:Item>

   </d:DIDL>

dim

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <dim:dim schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">

   1. <dim:field authority="caa9f1c1-ee14-4493-bf62-57fb60b03f23" confidence="600" element="contributor" mdschema="dc" qualifier="advisor">Sovadinová, Iva</dim:field>

   2. <dim:field authority="e9517554-4cd3-4e63-a560-4edd919b4a5d" confidence="600" element="contributor" mdschema="dc" qualifier="author">Martín Levy, Raquel</dim:field>

   3. <dim:field element="date" mdschema="dc" qualifier="accessioned">2021-08-30T12:03:46Z</dim:field>

   4. <dim:field element="date" mdschema="dc" qualifier="available">2021-08-30T12:03:46Z</dim:field>

   5. <dim:field element="date" mdschema="dc" qualifier="issued">2021</dim:field>

   6. <dim:field element="identifier" mdschema="dc" qualifier="uri">http://hdl.handle.net/10641/2409</dim:field>

   7. <dim:field element="description" lang="spa" mdschema="dc" qualifier="abstract">Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</dim:field>

   8. <dim:field element="description" lang="spa" mdschema="dc" qualifier="version">pre-print</dim:field>

   9. <dim:field element="description" lang="spa" mdschema="dc" qualifier="extent">1016 KB</dim:field>

   10. <dim:field element="language" lang="spa" mdschema="dc" qualifier="iso">eng</dim:field>

   11. <dim:field element="rights" lang="*" mdschema="dc">Atribución-NoComercial-SinDerivadas 3.0 España</dim:field>

   12. <dim:field element="rights" lang="*" mdschema="dc" qualifier="uri">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dim:field>

   13. <dim:field element="rights" lang="spa" mdschema="dc" qualifier="accessRights">openAccess</dim:field>

   14. <dim:field element="title" lang="spa" mdschema="dc">3D hepg2 cell-based cell transformation assay.</dim:field>

   15. <dim:field element="type" lang="spa" mdschema="dc">bachelorThesis</dim:field>

   </dim:dim>

etdms

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <thesis schemaLocation="http://www.ndltd.org/standards/metadata/etdms/1.0/ http://www.ndltd.org/standards/metadata/etdms/1.0/etdms.xsd">

   1. <title>3D hepg2 cell-based cell transformation assay.</title>

   2. <creator>Martín Levy, Raquel</creator>

   3. <contributor>Sovadinová, Iva</contributor>

   4. <description>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</description>

   5. <date>2021-08-30</date>

   6. <date>2021-08-30</date>

   7. <date>2021</date>

   8. <type>bachelorThesis</type>

   9. <identifier>http://hdl.handle.net/10641/2409</identifier>

   10. <language>eng</language>

   11. <rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</rights>

   12. <rights>openAccess</rights>

   13. <rights>Atribución-NoComercial-SinDerivadas 3.0 España</rights>

   </thesis>

marc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <record schemaLocation="http://www.loc.gov/MARC21/slim http://www.loc.gov/standards/marcxml/schema/MARC21slim.xsd">

   1. <leader>00925njm 22002777a 4500</leader>

   2. <datafield ind1=" " ind2=" " tag="042">

      1. <subfield code="a">dc</subfield>

      </datafield>

   3. <datafield ind1=" " ind2=" " tag="720">

      1. <subfield code="a">Martín Levy, Raquel</subfield>

      2. <subfield code="e">author</subfield>

      </datafield>

   4. <datafield ind1=" " ind2=" " tag="260">

      1. <subfield code="c">2021</subfield>

      </datafield>

   5. <datafield ind1=" " ind2=" " tag="520">

      1. <subfield code="a">Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</subfield>

      </datafield>

   6. <datafield ind1="8" ind2=" " tag="024">

      1. <subfield code="a">http://hdl.handle.net/10641/2409</subfield>

      </datafield>

   7. <datafield ind1="0" ind2="0" tag="245">

      1. <subfield code="a">3D hepg2 cell-based cell transformation assay.</subfield>

      </datafield>

   </record>

mets

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <mets ID=" DSpace_ITEM_10641-2409" OBJID=" hdl:10641/2409" PROFILE="DSpace METS SIP Profile 1.0" TYPE="DSpace ITEM" schemaLocation="http://www.loc.gov/METS/ http://www.loc.gov/standards/mets/mets.xsd">

   1. <metsHdr CREATEDATE="2022-09-20T09:27:47Z">

      1. <agent ROLE="CUSTODIAN" TYPE="ORGANIZATION">

         1. <name>DDFV</name>

         </agent>

      </metsHdr>

   2. <dmdSec ID="DMD_10641_2409">

      1. <mdWrap MDTYPE="MODS">

         1. <xmlData schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">

            1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">

               1. <mods:name>

                  1. <mods:role>

                     1. <mods:roleTerm type="text">advisor</mods:roleTerm>

                     </mods:role>

                  2. <mods:namePart>Sovadinová, Iva</mods:namePart>

                  </mods:name>

               2. <mods:name>

                  1. <mods:role>

                     1. <mods:roleTerm type="text">author</mods:roleTerm>

                     </mods:role>

                  2. <mods:namePart>Martín Levy, Raquel</mods:namePart>

                  </mods:name>

               3. <mods:extension>

                  1. <mods:dateAccessioned encoding="iso8601">2021-08-30T12:03:46Z</mods:dateAccessioned>

                  </mods:extension>

               4. <mods:extension>

                  1. <mods:dateAvailable encoding="iso8601">2021-08-30T12:03:46Z</mods:dateAvailable>

                  </mods:extension>

               5. <mods:originInfo>

                  1. <mods:dateIssued encoding="iso8601">2021</mods:dateIssued>

                  </mods:originInfo>

               6. <mods:identifier type="uri">http://hdl.handle.net/10641/2409</mods:identifier>

               7. <mods:abstract>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</mods:abstract>

               8. <mods:language>

                  1. <mods:languageTerm authority="rfc3066">eng</mods:languageTerm>

                  </mods:language>

               9. <mods:accessCondition type="useAndReproduction">Atribución-NoComercial-SinDerivadas 3.0 España</mods:accessCondition>

               10. <mods:titleInfo>

                   1. <mods:title>3D hepg2 cell-based cell transformation assay.</mods:title>

                   </mods:titleInfo>

               11. <mods:genre>bachelorThesis</mods:genre>

               </mods:mods>

            </xmlData>

         </mdWrap>

      </dmdSec>

   3. <amdSec ID="TMD_10641_2409">

      1. <rightsMD ID="RIG_10641_2409">

         1. <mdWrap MDTYPE="OTHER" MIMETYPE="text/plain" OTHERMDTYPE="DSpaceDepositLicense">

            1. <binData>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</binData>

            </mdWrap>

         </rightsMD>

      </amdSec>

   4. <amdSec ID="FO_10641_2409_1">

      1. <techMD ID="TECH_O_10641_2409_1">

         1. <mdWrap MDTYPE="PREMIS">

            1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">

               1. <premis:premis>

                  1. <premis:object>

                     1. <premis:objectIdentifier>

                        1. <premis:objectIdentifierType>URL</premis:objectIdentifierType>

                        2. <premis:objectIdentifierValue>http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf</premis:objectIdentifierValue>

                        </premis:objectIdentifier>

                     2. <premis:objectCategory>File</premis:objectCategory>

                     3. <premis:objectCharacteristics>

                        1. <premis:fixity>

                           1. <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>

                           2. <premis:messageDigest>fe245cd2537c822075f8fa614a8ed92a</premis:messageDigest>

                           </premis:fixity>

                        2. <premis:size>1040198</premis:size>

                        3. <premis:format>

                           1. <premis:formatDesignation>

                              1. <premis:formatName>application/pdf</premis:formatName>

                              </premis:formatDesignation>

                           </premis:format>

                        </premis:objectCharacteristics>

                     4. <premis:originalName>martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf</premis:originalName>

                     </premis:object>

                  </premis:premis>

               </xmlData>

            </mdWrap>

         </techMD>

      </amdSec>

   5. <amdSec ID="FT_10641_2409_4">

      1. <techMD ID="TECH_T_10641_2409_4">

         1. <mdWrap MDTYPE="PREMIS">

            1. <xmlData schemaLocation="http://www.loc.gov/standards/premis http://www.loc.gov/standards/premis/PREMIS-v1-0.xsd">

               1. <premis:premis>

                  1. <premis:object>

                     1. <premis:objectIdentifier>

                        1. <premis:objectIdentifierType>URL</premis:objectIdentifierType>

                        2. <premis:objectIdentifierValue>http://ddfv.ufv.es/bitstream/10641/2409/4/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt</premis:objectIdentifierValue>

                        </premis:objectIdentifier>

                     2. <premis:objectCategory>File</premis:objectCategory>

                     3. <premis:objectCharacteristics>

                        1. <premis:fixity>

                           1. <premis:messageDigestAlgorithm>MD5</premis:messageDigestAlgorithm>

                           2. <premis:messageDigest>cbb8dbfb879ecb4e28ec51c8e16fd92d</premis:messageDigest>

                           </premis:fixity>

                        2. <premis:size>61424</premis:size>

                        3. <premis:format>

                           1. <premis:formatDesignation>

                              1. <premis:formatName>text/plain</premis:formatName>

                              </premis:formatDesignation>

                           </premis:format>

                        </premis:objectCharacteristics>

                     4. <premis:originalName>martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt</premis:originalName>

                     </premis:object>

                  </premis:premis>

               </xmlData>

            </mdWrap>

         </techMD>

      </amdSec>

   6. <fileSec>

      1. <fileGrp USE="ORIGINAL">

         1. <file ADMID="FO_10641_2409_1" CHECKSUM="fe245cd2537c822075f8fa614a8ed92a" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10641_2409_1" ID="BITSTREAM_ORIGINAL_10641_2409_1" MIMETYPE="application/pdf" SEQ="1" SIZE="1040198">

            1. <FLocat LOCTYPE="URL" href="http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf" type="simple" />

            </file>

         </fileGrp>

      2. <fileGrp USE="TEXT">

         1. <file ADMID="FT_10641_2409_4" CHECKSUM="cbb8dbfb879ecb4e28ec51c8e16fd92d" CHECKSUMTYPE="MD5" GROUPID="GROUP_BITSTREAM_10641_2409_4" ID="BITSTREAM_TEXT_10641_2409_4" MIMETYPE="text/plain" SEQ="4" SIZE="61424">

            1. <FLocat LOCTYPE="URL" href="http://ddfv.ufv.es/bitstream/10641/2409/4/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt" type="simple" />

            </file>

         </fileGrp>

      </fileSec>

   7. <structMap LABEL="DSpace Object" TYPE="LOGICAL">

      1. <div ADMID="DMD_10641_2409" TYPE="DSpace Object Contents">

         1. <div TYPE="DSpace BITSTREAM">

            1. <fptr FILEID="BITSTREAM_ORIGINAL_10641_2409_1" />

            </div>

         </div>

      </structMap>

   </mets>

mods

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <mods:mods schemaLocation="http://www.loc.gov/mods/v3 http://www.loc.gov/standards/mods/v3/mods-3-1.xsd">

   1. <mods:name>

      1. <mods:namePart>Martín Levy, Raquel</mods:namePart>

      </mods:name>

   2. <mods:extension>

      1. <mods:dateAvailable encoding="iso8601">2021-08-30T12:03:46Z</mods:dateAvailable>

      </mods:extension>

   3. <mods:extension>

      1. <mods:dateAccessioned encoding="iso8601">2021-08-30T12:03:46Z</mods:dateAccessioned>

      </mods:extension>

   4. <mods:originInfo>

      1. <mods:dateIssued encoding="iso8601">2021</mods:dateIssued>

      </mods:originInfo>

   5. <mods:identifier type="uri">http://hdl.handle.net/10641/2409</mods:identifier>

   6. <mods:abstract>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</mods:abstract>

   7. <mods:language>

      1. <mods:languageTerm>eng</mods:languageTerm>

      </mods:language>

   8. <mods:accessCondition type="useAndReproduction">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</mods:accessCondition>

   9. <mods:accessCondition type="useAndReproduction">openAccess</mods:accessCondition>

   10. <mods:accessCondition type="useAndReproduction">Atribución-NoComercial-SinDerivadas 3.0 España</mods:accessCondition>

   11. <mods:titleInfo>

       1. <mods:title>3D hepg2 cell-based cell transformation assay.</mods:title>

       </mods:titleInfo>

   12. <mods:genre>bachelorThesis</mods:genre>

   </mods:mods>

ore

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <atom:entry schemaLocation="http://www.w3.org/2005/Atom http://www.kbcafe.com/rss/atom.xsd.xml">

   1. <atom:id>http://hdl.handle.net/10641/2409/ore.xml</atom:id>

   2. <atom:link href="http://hdl.handle.net/10641/2409" rel="alternate" />
   3. <atom:link href="http://hdl.handle.net/10641/2409/ore.xml" rel="http://www.openarchives.org/ore/terms/describes" />
   4. <atom:link href="http://hdl.handle.net/10641/2409/ore.xml#atom" rel="self" type="application/atom+xml" />

   5. <atom:published>2021-08-30T12:03:46Z</atom:published>

   6. <atom:updated>2021-08-30T12:03:46Z</atom:updated>

   7. <atom:source>

      1. <atom:generator>DDFV</atom:generator>

      </atom:source>

   8. <atom:title>3D hepg2 cell-based cell transformation assay.</atom:title>

   9. <atom:author>

      1. <atom:name>Martín Levy, Raquel</atom:name>

      </atom:author>

   10. <atom:category label="Aggregation" scheme="http://www.openarchives.org/ore/terms/" term="http://www.openarchives.org/ore/terms/Aggregation" />
   11. <atom:category scheme="http://www.openarchives.org/ore/atom/modified" term="2021-08-30T12:03:46Z" />
   12. <atom:category label="DSpace Item" scheme="http://www.dspace.org/objectModel/" term="DSpaceItem" />
   13. <atom:link href="http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf" length="1040198" rel="http://www.openarchives.org/ore/terms/aggregates" title="martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf" type="application/pdf" />

   14. <oreatom:triples>

       1. <rdf:Description about="http://hdl.handle.net/10641/2409/ore.xml#atom">

          1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceItem" />

          2. <dcterms:modified>2021-08-30T12:03:46Z</dcterms:modified>

          </rdf:Description>

       2. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf">

          1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

          2. <dcterms:description>ORIGINAL</dcterms:description>

          </rdf:Description>

       3. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2409/2/license_rdf">

          1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

          2. <dcterms:description>CC-LICENSE</dcterms:description>

          </rdf:Description>

       4. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2409/3/license.txt">

          1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

          2. <dcterms:description>LICENSE</dcterms:description>

          </rdf:Description>

       5. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2409/4/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt">

          1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

          2. <dcterms:description>TEXT</dcterms:description>

          </rdf:Description>

       6. <rdf:Description about="http://ddfv.ufv.es/bitstream/10641/2409/5/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.jpg">

          1. <rdf:type resource="http://www.dspace.org/objectModel/DSpaceBitstream" />

          2. <dcterms:description>THUMBNAIL</dcterms:description>

          </rdf:Description>

       </oreatom:triples>

   </atom:entry>

qdc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <qdc:qualifieddc schemaLocation="http://purl.org/dc/elements/1.1/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dc.xsd http://purl.org/dc/terms/ http://dublincore.org/schemas/xmls/qdc/2006/01/06/dcterms.xsd http://dspace.org/qualifieddc/ http://www.ukoln.ac.uk/metadata/dcmi/xmlschema/qualifieddc.xsd">

   1. <dc:title>3D hepg2 cell-based cell transformation assay.</dc:title>

   2. <dc:creator>Martín Levy, Raquel</dc:creator>

   3. <dc:contributor>Sovadinová, Iva</dc:contributor>

   4. <dcterms:abstract>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</dcterms:abstract>

   5. <dcterms:dateAccepted>2021-08-30T12:03:46Z</dcterms:dateAccepted>

   6. <dcterms:available>2021-08-30T12:03:46Z</dcterms:available>

   7. <dcterms:created>2021-08-30T12:03:46Z</dcterms:created>

   8. <dcterms:issued>2021</dcterms:issued>

   9. <dc:type>bachelorThesis</dc:type>

   10. <dc:identifier>http://hdl.handle.net/10641/2409</dc:identifier>

   11. <dc:language>eng</dc:language>

   12. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>

   13. <dc:rights>openAccess</dc:rights>

   14. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>

   </qdc:qualifieddc>

rdf

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <rdf:RDF schemaLocation="http://www.openarchives.org/OAI/2.0/rdf/ http://www.openarchives.org/OAI/2.0/rdf.xsd">

   1. <ow:Publication about="oai:ddfv.ufv.es:10641/2409">

      1. <dc:title>3D hepg2 cell-based cell transformation assay.</dc:title>

      2. <dc:creator>Martín Levy, Raquel</dc:creator>

      3. <dc:contributor>Sovadinová, Iva</dc:contributor>

      4. <dc:description>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</dc:description>

      5. <dc:date>2021-08-30T12:03:46Z</dc:date>

      6. <dc:date>2021-08-30T12:03:46Z</dc:date>

      7. <dc:date>2021</dc:date>

      8. <dc:type>bachelorThesis</dc:type>

      9. <dc:identifier>http://hdl.handle.net/10641/2409</dc:identifier>

      10. <dc:language>eng</dc:language>

      11. <dc:rights>http://creativecommons.org/licenses/by-nc-nd/3.0/es/</dc:rights>

      12. <dc:rights>openAccess</dc:rights>

      13. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>

      </ow:Publication>

   </rdf:RDF>

uketd_dc

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <uketd_dc:uketddc schemaLocation="http://naca.central.cranfield.ac.uk/ethos-oai/2.0/ http://naca.central.cranfield.ac.uk/ethos-oai/2.0/uketd_dc.xsd">

   1. <dc:title>3D hepg2 cell-based cell transformation assay.</dc:title>

   2. <dc:creator>Martín Levy, Raquel</dc:creator>

   3. <uketdterms:advisor>Sovadinová, Iva</uketdterms:advisor>

   4. <dcterms:abstract>Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</dcterms:abstract>

   5. <dcterms:issued>2021</dcterms:issued>

   6. <dc:type>bachelorThesis</dc:type>

   7. <dc:language type="dcterms:ISO639-2">eng</dc:language>

   8. <dcterms:isReferencedBy>http://hdl.handle.net/10641/2409</dcterms:isReferencedBy>

   9. <dc:identifier type="dcterms:URI">http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf</dc:identifier>

   10. <uketdterms:checksum type="uketdterms:MD5">fe245cd2537c822075f8fa614a8ed92a</uketdterms:checksum>

   11. <dcterms:license>http://ddfv.ufv.es/bitstream/10641/2409/3/license.txt</dcterms:license>

   12. <uketdterms:checksum type="uketdterms:MD5">8b6e3a0bc6a1ca51936267b0e6e4740c</uketdterms:checksum>

   13. <dcterms:hasFormat>http://ddfv.ufv.es/bitstream/10641/2409/4/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt</dcterms:hasFormat>

   14. <uketdterms:checksum type="uketdterms:MD5">cbb8dbfb879ecb4e28ec51c8e16fd92d</uketdterms:checksum>

   15. <dc:rights>Atribución-NoComercial-SinDerivadas 3.0 España</dc:rights>

   </uketd_dc:uketddc>

xoai

Descarregar XML

<?xml version="1.0" encoding="UTF-8" ?>

1. <metadata schemaLocation="http://www.lyncode.com/xoai http://www.lyncode.com/xsd/xoai.xsd">

   1. <element name="dc">

      1. <element name="contributor">

         1. <element name="advisor">

            1. <element name="none">

               1. <field name="value">Sovadinová, Iva</field>

               2. <field name="authority">caa9f1c1-ee14-4493-bf62-57fb60b03f23</field>

               3. <field name="confidence">600</field>

               </element>

            </element>

         2. <element name="author">

            1. <element name="none">

               1. <field name="value">Martín Levy, Raquel</field>

               2. <field name="authority">e9517554-4cd3-4e63-a560-4edd919b4a5d</field>

               3. <field name="confidence">600</field>

               </element>

            </element>

         </element>

      2. <element name="date">

         1. <element name="accessioned">

            1. <element name="none">

               1. <field name="value">2021-08-30T12:03:46Z</field>

               </element>

            </element>

         2. <element name="available">

            1. <element name="none">

               1. <field name="value">2021-08-30T12:03:46Z</field>

               </element>

            </element>

         3. <element name="issued">

            1. <element name="none">

               1. <field name="value">2021</field>

               </element>

            </element>

         </element>

      3. <element name="identifier">

         1. <element name="uri">

            1. <element name="none">

               1. <field name="value">http://hdl.handle.net/10641/2409</field>

               </element>

            </element>

         </element>

      4. <element name="description">

         1. <element name="abstract">

            1. <element name="spa">

               1. <field name="value">Monolayer in vitro cultures of hepatic cells, so-called two-dimensional (2D) liver models do not adequately mimic the natural cell microenvironment because of the lack of different biological features and functions such as cell-to-cell and cell-to-matrix interactions. That is why there is a need to develop and improve three-dimensional (3D) hepatic cell (liver) models, characterized by higher expression of liver cell markers and cell interactions, although they still present some limitations and special requirements. This study aims to optimize and adapt 3D HepG2 cell-based transformation assay applicable for biomedicine, carcinogenicity research and toxicology. Within the proposed protocol, HepG2 cells spheroids were first exposed to an initiator (3-methylcholanthrene, 3-MC) followed by the exposure to promotor (12-O-tetradecanoylphorbol-13- acetate, TPA) to create a tumor environment and characterize a new hepatocellular carcinoma in vitro model. The spheroids were monitored within a culture with a non-destructive and non-invasive bright field microscopy-based assay. The analysis is suitable with manual high-speed automated microscopic image acquisition and automated analysis using an in-house built macro 'Spheroid_Finder' in Fiji/ImageJ software. This protocol was essential to characterize and quantify 3D spheroid formation, size and shape. The results show that spheroids treated with solvent controls did not differ from non-treated spheroids in size or shape. Interestingly, the spheroids treated with 3-MC alone and with the combination with TPA were smaller than the control spheroids, and their shape and compactness were also affected. On the other hand, spheroids treated with TPA alone were mildly bigger than the control ones, and their shape and compactness were changed. It should be emphasized that to confirm cell transformation, the gene expression related to neoplastic and hepatocellular carcinoma-derived cell lines phenotypes will be further evaluated with RT-qPCR, as well as spheroids functionality by measuring albumin, urea or lactate in the collected medium. Despite this assay needing further optimization and validation to confirm its potential, we conclude that CTA assay utilizing HepG2 3D spheroids can be a promising tool for screening carcinogenicity potential of chemicals or new anti-cancer in biomedical, pharmacological, and toxicological research.</field>

               </element>

            </element>

         2. <element name="version">

            1. <element name="spa">

               1. <field name="value">pre-print</field>

               </element>

            </element>

         3. <element name="extent">

            1. <element name="spa">

               1. <field name="value">1016 KB</field>

               </element>

            </element>

         </element>

      5. <element name="language">

         1. <element name="iso">

            1. <element name="spa">

               1. <field name="value">eng</field>

               </element>

            </element>

         </element>

      6. <element name="rights">

         1. <element name="*">

            1. <field name="value">Atribución-NoComercial-SinDerivadas 3.0 España</field>

            </element>

         2. <element name="uri">

            1. <element name="*">

               1. <field name="value">http://creativecommons.org/licenses/by-nc-nd/3.0/es/</field>

               </element>

            </element>

         3. <element name="accessRights">

            1. <element name="spa">

               1. <field name="value">openAccess</field>

               </element>

            </element>

         </element>

      7. <element name="title">

         1. <element name="spa">

            1. <field name="value">3D hepg2 cell-based cell transformation assay.</field>

            </element>

         </element>

      8. <element name="type">

         1. <element name="spa">

            1. <field name="value">bachelorThesis</field>

            </element>

         </element>

      </element>

   2. <element name="bundles">

      1. <element name="bundle">

         1. <field name="name">ORIGINAL</field>

         2. <element name="bitstreams">

            1. <element name="bitstream">

               1. <field name="name">martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf</field>

               2. <field name="originalName">martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf</field>

               3. <field name="description" />

               4. <field name="format">application/pdf</field>

               5. <field name="size">1040198</field>

               6. <field name="url">http://ddfv.ufv.es/bitstream/10641/2409/1/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf</field>

               7. <field name="checksum">fe245cd2537c822075f8fa614a8ed92a</field>

               8. <field name="checksumAlgorithm">MD5</field>

               9. <field name="sid">1</field>

               </element>

            </element>

         </element>

      2. <element name="bundle">

         1. <field name="name">CC-LICENSE</field>

         2. <element name="bitstreams">

            1. <element name="bitstream">

               1. <field name="name">license_rdf</field>

               2. <field name="originalName">license_rdf</field>

               3. <field name="format">application/rdf+xml; charset=utf-8</field>

               4. <field name="size">811</field>

               5. <field name="url">http://ddfv.ufv.es/bitstream/10641/2409/2/license_rdf</field>

               6. <field name="checksum">4d01a8abc68801ab758ec8c2c04918c3</field>

               7. <field name="checksumAlgorithm">MD5</field>

               8. <field name="sid">2</field>

               </element>

            </element>

         </element>

      3. <element name="bundle">

         1. <field name="name">LICENSE</field>

         2. <element name="bitstreams">

            1. <element name="bitstream">

               1. <field name="name">license.txt</field>

               2. <field name="originalName">license.txt</field>

               3. <field name="format">text/plain; charset=utf-8</field>

               4. <field name="size">2418</field>

               5. <field name="url">http://ddfv.ufv.es/bitstream/10641/2409/3/license.txt</field>

               6. <field name="checksum">8b6e3a0bc6a1ca51936267b0e6e4740c</field>

               7. <field name="checksumAlgorithm">MD5</field>

               8. <field name="sid">3</field>

               </element>

            </element>

         </element>

      4. <element name="bundle">

         1. <field name="name">TEXT</field>

         2. <element name="bitstreams">

            1. <element name="bitstream">

               1. <field name="name">martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt</field>

               2. <field name="originalName">martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt</field>

               3. <field name="description">Extracted text</field>

               4. <field name="format">text/plain</field>

               5. <field name="size">61424</field>

               6. <field name="url">http://ddfv.ufv.es/bitstream/10641/2409/4/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.txt</field>

               7. <field name="checksum">cbb8dbfb879ecb4e28ec51c8e16fd92d</field>

               8. <field name="checksumAlgorithm">MD5</field>

               9. <field name="sid">4</field>

               </element>

            </element>

         </element>

      5. <element name="bundle">

         1. <field name="name">THUMBNAIL</field>

         2. <element name="bitstreams">

            1. <element name="bitstream">

               1. <field name="name">martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.jpg</field>

               2. <field name="originalName">martínlevyraquel_2358_1157060_MARTÍN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.jpg</field>

               3. <field name="description">Generated Thumbnail</field>

               4. <field name="format">image/jpeg</field>

               5. <field name="size">1743</field>

               6. <field name="url">http://ddfv.ufv.es/bitstream/10641/2409/5/mart%c3%adnlevyraquel_2358_1157060_MART%c3%8dN_LEVY_RAQUEL_TFG_4ABiomedicina.pdf.jpg</field>

               7. <field name="checksum">d6eefa646229a3dc849a819023840a0a</field>

               8. <field name="checksumAlgorithm">MD5</field>

               9. <field name="sid">5</field>

               </element>

            </element>

         </element>

      </element>

   3. <element name="others">

      1. <field name="handle">10641/2409</field>

      2. <field name="identifier">oai:ddfv.ufv.es:10641/2409</field>

      3. <field name="lastModifyDate">2021-08-31 02:00:22.947</field>

      </element>

   4. <element name="repository">

      1. <field name="name">DDFV</field>

      2. <field name="mail">dspace@ufv.es</field>

      </element>

   5. <element name="license">

      1. <field name="bin">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</field>

      </element>

   </metadata>